Logical Therapeutics pockets $30M in VC

Logical Therapeutics--which is developing new therapies for inflammatory diseases--has garnered $30 million in its second round of venture capital, which was led by SV Life Sciences. Other investors participating in the Series B financing include Burrill & Company, Novo A/S and Sigvion Capital and PA Early Stage Partners, which provided the seed funding for Logical last July. The funding will allow Logical to advance multiple drug candidates, including its lead drug, LT-NS001, a naproxen pro-drug, through proof-of-concept clinical trials.

- check out the release

ALSO: Copenhagen-based Astion Pharma has received DKK 50 million of fresh capital from its existing shareholders to accelerate Phase III of its dermatological drug candidate ASF-1096. Release

PLUS: WaferGen Bio-systems announced the second closing of a private placement that has brought in $12 million. Release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.